Expression of the RIa subunit of cAMP-dependent protein kinase type I is increased in human cancers in which an autocrine pathway for epidermal growth factorrelated growth factors is activated. We have investigated the eect of sequence-speci®c inhibition of RIa gene expression on ovarian cancer cell growth. We report that RIa antisense treatment results in a reduction in RIa expression and protein kinase A type I, and inhibition of cell growth. The growth inhibition was accompanied by changes in cell morphology and appearance of apoptotic nuclei. In addition, EGF receptor, c-erbB-2 and c-erbB-3 levels were reduced, and the basal and EGF-stimulated mitogen-activated protein kinase activities were reduced. Protein kinase A type I and EGF receptor levels were also reduced in cells overexpressing EGF receptor antisense cDNA. These results suggest that the antisense depletion of RIa leads to blockade of both the serinethreonine kinase and the tyrosine kinase signaling pathways resulting in arrest of ovarian cancer cell growth.
The ability to block expression of individual genes that are causally related to diseases provides a powerful means to explore the molecular basis of diseases as well as the opportunity for therapeutic intervention. There is growing evidence supporting that the sequencespeci®c inhibition of gene expression by the use of antisense oligonucleotides can be a promising therapeutic innovation toward treatment of cancer and other diseases (Cho-Chung, 1996; Dean et al., 1996; Monia et al., 1996) .
Cyclic AMP (cAMP) regulates various cellular functions, such as metabolism, secretion, cell proliferation, dierentiation and gene induction, through the activation of cAMP-dependent protein kinases (PKA) (Krebs and Beavo, 1979) . There are two types of PKA, type I (PKA-I) and type II (PKA-II), which share a common catalytic (C) subunit but contain dierent regulatory (R) subunits, RI and RII, respectively (Beebe and Corbin, 1986) . Four isoforms of the R subunits, RIa, RIb, RIIa and RIIb, have been identi®ed (McKnight et al., 1988; Levy et al., 1988) . Importantly, dierential expression of PKA-I and II has been correlated with cell dierentiation and neoplastic transformation. RI/PKA-I is preferentially expressed in transformed cells or during early stages of ontogenesis (Lohmann and Walter, 1984; Cho-Chung, 1990) , whereas expression of RII/PKA-II is induced in cancer cells growth arrested following treatment with cAMP analogs or dierentiating agents (Schwartz and Rubin, 1985; Cho-Chung et al., 1989) . Thus, the dual signals toward cell growth, positive and negative, transduced by cAMP may depend on the availability of RI and RII subunits, respectively.
It has been hypothesized that the RIa is an ontogenic growth-inducing protein, and its constitutive expression disrupts normal ontogenic processes, resulting in a pathogenic outgrowth, such as malignancy (Cho-Chung, 1990 ). Subsequently, it has been shown, through antisense strategy, that RIa has a role in neoplastic cell growth in vitro (Tortora et al., 1991; Yokozaki et al., 1993; Srivastava et al., 1998) and in vivo Cho-Chung et al., 1997) .
The epidermal growth factor (EGF)-related growth factors play a role in human cancer growth through autocrine and paracrine mechanisms (Aaronson, 1991) . EGF-like growth factors, such as transforming growth factor-a (TGFa), bind to the extracellular domain of the EGF receptor (EGF-R) and activate its intracellular tyrosine kinase domain. Enhanced expression of TGFa and/or EGF-R has been detected in a majority of human carcinomas examined (Aaronson, 1991) .
Functional interactions between PKA and EGF-R signaling pathways have been suggested. ras-and TGFa-dependent transformation brought about an early induction of RIa/PKA, while selective downregulation of RIa/PKA-I resulted in inhibition of TGFa-and p21 ras-signaling Ciardiello et al., 1990) .
In the present study, we have examined the eect of the sequence-speci®c inhibition of RIa gene expression on the growth of OVCAR-8 ovarian cancer cells. We also examined the eect of RIa antisense on the EGF-R signaling pathway and, conversely, the eect of EGF-R antisense gene overexpression on the RIa/ PKA-I expression in OVCAR-8 cells. We used a mixed backbone RIa antisense, namely phosphorothioate oligodeoxynucleotide (PS-oligo DNA), containing segments composed of PS-2'-O-methyloligo RNA, which combines the favorable antisense properties of PS-oligo DNA (RNase H activation) and of PS-2'-Omethyloligo RNA (increase in nuclease resistance and duplex stability). Such mixed backbone (hybrid) oligonucleotides have been shown to have improved antisense activity over PS-oligonucleotides (Metelev et al., 1994; Cho-Chung et al., 1997) . As control, we used 4-base mismatched oligonucleotide and random sequence oligonucleotide.
We examined the eect of one time treatment (at 5 h after seeding) of RIa antisense oligonucleotide on the monolayer growth of OVCAR-8 cells. Cationic lipid, N -[1 -(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), was used in all cell culture experiments to facilitate intracellular uptake of oligonucleotides (Srivastava et al., 1998) . The antisense treatment resulted in inhibition of cell proliferation in a time-and concentration-dependent manner exhibiting a 75% inhibition at 200 nM by day 5 (Figure 1a ). The growth inhibition was not due to the nonspeci®c cytotoxicity since over 90% of the cells were viable at 5 days post antisense treatment. By comparison, 4-base mismatched ( Figure 1a ) and random sequence control (data not shown) oligonucleotides had little (515%) or no growth inhibitory eect. We next examined the antisense eect on the anchorage-independent growth of OVCAR-8 cells. RIa antisense at 1, 3 and 5 mM concentrations in the absence of DOTAP produced inhibition of the colony formation of cells in soft agar in a dose-dependent manner (Figure 1b) . Four-base mismatched oligonucleotide had no eect on colony formation at 1 and 3 mM concentrations, but had a minimum inhibitory eect at 5 mM concentration (Figure 1b) .
We examined whether RIa antisense could specifically inhibit the RIa gene expression. RIa antisense treatment for 5 days at 150 nM concentration brought about a marked reduction in RIa mRNA level ( Figure  2a 1610 4 ) were seeded in 1 ml of 0.3% Difco Noble agar (Difco, Detroit, MI, USA) in culture medium. This suspension was layered over 1 ml of 0.6% agar-medium base layer in 6-well plates. The antisense and control oligonucleotides were added in the top and base layers. After 7 days of incubation, an additional 1 ml of medium containing the oligonucleotides was added to the plates. After 14 days, control (C) and oligonucleotide treated cells were stained with nitro blue tetrazolium (Sigma). Colonies larger than 0.2 mm were counted with an Artek 880 colony counter (Artek Systems, Inc., Farmingdale, NY, USA). The data represent average values of three independent experiments lane 8) and RIIb protein was not detected in both antisense-treated and untreated cells (Figure 2b ). Quanti®cation by densitometric tracings of autoradiographs (Figure 2b) showed that the RIa and RIIa protein levels in the antisense treated cells were 10 and 90%, respectively, of those in untreated control cells. The sequence-speci®c eect of RIa antisense was clearly demonstrated by the 4-base mismatched (Figure 2 ) and random sequence (data not shown) control oligonucleotides that could not mimic the antisense eect of RIa downregulation.
The above data showed that upon antisense treatment, the RIa expression at both mRNA and protein levels sharply decreased. In cells, RIa can exist either in its subunit form or in the form of the PKA-I holoenzyme. As the RIa subunit can act as a cAMP sink, RIa in the holoenzyme complex may be of functional importance. Therefore, we examined whether RIa antisense could in¯uence the PKA isozyme distribution in OVCAR-8 cells. Cell extracts were subjected to diethyl-aminoethyldextran (DEAE) ion-exchange chromatography, and fractions were assayed for PKA activity in the absence and presence of cAMP. Saline-treated control cells showed two major peaks of PKA, PKA-I (Figure 3 , peak I) and PKA-II (Figure 3 , peak II), that were eluted at 40 ± 80 mM and 220 ± 300 mM NaCl, respectively, as was Figure 2 Sequence-speci®c inhibition of RIa gene expression. (a) RIa antisense eect on the mRNAs of PKA R and C subunit. The total RNAs isolated from untreated control (C) and antisense (AS) or control mismatched oligonucleotide (MO)-treated (for 5 days at 150 nM) cells were subjected to Northern blotting analysis using 32 P-labeled cDNA probes as indicated. Total cellular RNA preparation, Northern blot analysis and hybridization of RNA with 32 P-labeled DNA probes were as described earlier (Nesterova et al., 1996) . DNA was labeled with a-32 P-dCTP according to a standard protocol for nick translation reactions using an Amersham nick translation kit. The speci®c radioactivity of labeled DNA equaled 3.7610 6 c.p.m./mg DNA. Data represent one of three independent experiments that gave similar results. (b) Photoanity labeling-immunoprecipitation of PKA R subunits. Cell extracts from cells untreated (C) and treated with antisense (AS) or control mismatched oligonucleotide (MO) as in a above were photoanity-labeled with 8-N 3 -
32
[P]cAMP, immunoprecipitated with each R subunit antibodies, then subjected to SDS ± PAGE. Cell extract preparation and the photoactivated incorporation of 8-N 3 -[ 32 P]cAMP, immunoprecipitation using anti-RIa, anti-RIIa and anti-RIIb polyclonal antibodies and SDS ± PAGE of the dissolved immunoprecipitates were performed as described previously . The data represent one of three independent experiments that gave similar results for two cysteine-rich and transmembrane domains of EGF-R was blunted with T4 DNA polymerase and ligated to NotI linkers as described previously (Pegues and Stromberg, 1997 ). An expression vector pOPRSVI (Stratagene, La Jolla, CA, USA) was restricted with NotI, dephosphorylated with calf intestinal phosphatase and gel puri®ed. The NotI modi®ed 1.8 kb fragment was cloned into the NotI site of pOPRSVI in both sense and antisense orientation, which was determined by restriction analysis. OVCAR-8 ovarian cancer cells were stably transfected with EGF-R sense and antisense expression vectors, and the expanded clones were used in the experiment. Cell extracts (10 mg protein) of control (untreated) and RIa antisense-treated (150 nM for 5 days) or of EGF-R antisense gene overexpressing cells were subjected to DEAE chromatography (1610 cm columns) and the column eluents were assayed for protein kinase A activity in the absence (*) and presence (.) of 5 mM cAMP by the method described previously . The experiments were repeated 2 ± 3 times, and reproducible elution pro®les were obtained. The salt concentrations were determined by the measurement of the conductivity. I, PKA-I; II, PKA II. The PKA-I and PKA-II activities were calculated by the area estimation of the peak I and II (i.e., activity in (+) cAMP minus activity in (7) cAMP Protein kinase A antisense inhibition of ovarian cancer cell growth O È Alper et al shown previously in other cells (Figure 3) (Nesterova et al., 1996) . The antisense treatment (150 nM, for 5 days) selectively eliminated PKA-I, the RIa-containing holoenzyme without changing PKA-II activity ( Figure  3 ). The antisense, however, brought about changes in the PKA-II pro®le of the cell. The control cells contained PKA-II with its peak eluted at 230 mM NaCl, whereas the antisense-treated cells contained the PKA-II with its peak eluted at 280 mM NaCl prominently (Figure 3) . The PKA elution pro®le observed at a wide salt concentration range (200 ± 300 mM NaCl) has been associated with the presence of multiple kinase species including either RII 2 C trimer or RII 2 C 2 tetramer with nonsaturating amounts of cAMP bound and cAMP unbound form (Cobb et al., 1987) , the phosphorylated versus unphosphorylated (Nesterova et al., 1996; Budillon et al., 1995) and the RIIa versus RIIb-containing PKA-II (Otten et al., 1991; Nesterova et al., 1996) . The RIIa-containing PKA-II elutes at a higher salt concentration than the RIIb-containing PKA-II, and PKA-II containing the mutant RIIb lacking the autophosphorylation site elutes at a lower salt concentration than the wild-type RIIb-containing PKA-II (Budillon et al., 1995) . OVCAR-8 cells contained RIIa but not RIIb ( Figure  2) . Thus, the PKA-II induced by RIa antisense treatment may represent the RIIa-containing PKA-II in which RIIa may be phosphorylated as its peak shifts toward a higher salt concentration (Figure 3 ). Fourbase mismatched oligonucleotide treatment had no eect on the amount and pro®le of PKA-I and PKA-II in these cells (data not shown).
Antisense EGF-R cDNA transfection has been shown to impair cell proliferation in cancer cells (Ciardiello et al., 1998) . To investigate the crosstalk between PKA and tyrosine kinase pathways, OVCAR-8 cells were transfected with the plasmid containing EGF-R cDNA in the antisense orientation. The clones that show retarded growth, cell morphology changes and the low levels of EGF-R protein (Alper et al., 1998) were examined for their PKA isozyme pro®le. Strikingly, the PKA pro®le of the antisense EGF-R cDNA transfectants was almost identical to that of the parental cells treated with the RIa antisense (Figure 3) . The sense EGF-R cDNA transfectants exhibited the same PKA pro®le as that of nontransfectant parental cells (data not shown).
Our data that the selective downregulation of PKA-I without changing the level of PKA-II in EGF-Rantisense gene transfectants (Figure 3 ) suggest the possible crosstalk between PKA and tyrosine kinase signaling pathways. We therefore examined the eect of RIa antisense treatment on EGF-R, c-erbB-2, cerbB-3 and c-erbB-4 protein levels in OVCAR-8 cells. Treatment of cells with RIa antisense (150 nM, 5 days) markedly reduced EGF-R, c-erbB-2 and c-erbB-3 levels (Figure 4) . Quanti®cation by densitometric tracings of the bands showed that these receptor levels in the antisense treated cells were 510% of that in the untreated control cells. The mismatched oligonucleotide could not mimic the eect of RIa antisense (Figure 4) . However, c-erbB-4 expression was not downregulated but was upregulated (*twofold) non-sequence speci®cally by the both antisense and control antisense oligonucleotide treatment (Figure 4 ).
The morphology of OVCAR-8 cells treated with RIa antisense was examined by staining with Giemsa (data not shown). Control cells exhibited a small, roundshaped morphology and grew in piling up fashion over other cells exhibiting pseudopodic behavior. RIa antisense treatment (150 nM, 5 days) brought about an elongated cell shape, increased cytoplasm to nucleus ratio,¯at phenotype and sparse growth. The 4-base mismatched oligonucleotide failed to produce any morphological change. Because the antisense treatment brought about cell growth inhibition (Figure 1) , we examined whether apoptosis (programmed cell death) was involved in the growth inhibition. Treatment of cells with RIa antisense (150 nM, 5 days) caused induction of apoptosis as evident from fragmented nuclei and/or condensed chromatin (data not shown). In contrast, mismatched oligo had no eect on apoptosis.
The mitogen-activated protein kinases (MAP kinases), p 42 mapk and p 44 mapk , also called ERK-1 and ERK-2, are rapidly activated in cells stimulated with Figure 4 RIa antisense downregulates EGF-receptor and c-erbB proteins. Cell extracts from untreated control (C) and RIa antisense (AS) or control mismatched oligonucleotide (MO)-treated cells (150 nM for 5 days) were subjected to immunoprecipitation followed by Western blotting analysis for EGF-R and c-erbB proteins. Western blot analysis: Cells (1610 6 ) were washed with PBS and lysed in`Buer 10' (Nesterova et al., 1996) . Cell lysates were immunoprecipitated with anti-EGF-R antibody (LA-1) (Upstate Biotechnology, Lake Placid, NY, USA), anti-c-erbB-2 antibody (Ab-3) (Oncogene Research Products, Cambridge, MA, USA), anti-c-erbB-3 antibody (c-17) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-c-erbB-4 antibody (Ab-1) (Neomarkers, Fremont, CA, USA) at 48C overnight. The immunoprecipitates were incubated with Protein A sepharose at 48C for 2 h, proteins bound to protein A-sepharose were recovered by centrifugation, released by heating, resolved by 4 ± 12% SDS ± PAGE and transferred to nitrocellulose sheets. The blots were ®rst incubated with 4% non-fat dry milk for 1 h at room temperature and then probed with antibodies speci®c to EGF-R (1005) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), c-erbB-2 (Ab-3), c-erbB-3 (c-17) and c-erbB-4 (Ab-2) (Neomarkers, Fremont, CA, USA). Horseradish peroxidase was used as secondary antibody. Immunodection was performed using enhanced chemiluminescence method recommended by the manufacturer (Amersham Pharmacia Biotech). The data represent one of three independent experiments that gave similar results
Protein kinase A antisense inhibition of ovarian cancer cell growth O È Alper et al various extracellular signals. They are thought to play a pivotal role in integrating and transmitting transmembrane signals required for growth and differentiation (Sturgill et al., 1988; Davis, 1993) . Because both RIa antisense treatment and EGF-R antisense gene overexpression resulted in inhibition of cell growth and changes in cell morphology, we examined whether alteration in MAP kinase activity is involved in the growth inhibitory eects. The untreated control cells exhibited the maximum activation of MAP kinase after 4 min of EGF stimulation (data not shown). In RIa antisense-treated cells, the basal and EGF-stimulated MAP kinase activities were greatly reduced as compared to the control cells. In contrast, in EGF-R antisense gene overexpressing cells, the MAP kinase was constitutively activated to a high level and no longer stimulated with EGF. The control oligonucleotide treatment or EGF-R sense gene overexpression had no eect on MAP kinase activity.
In the present study we have shown that the RIa antisense treatment results in a reduction of RIa expression at both the mRNA and protein levels, inhibition of cell growth, changes in cell morphology and induction of apoptosis in OVCAR-8 ovarian cancer cells. The growth inhibition may have been due to the eect other than the blockade of RIa expression as nonspeci®c binding of oligonucleotides or its degradation products to biological targets has been shown (Stein, 1995) . As discussed below, however, our data show that the antisense inhibition of RIa expression and modulation of protein kinase A isozymes are clearly related to the inhibition of OVCAR-8 cell growth. Thus, at most, nonspeci®c binding of oligonucleotide probably played a minimal role, if any, in the observed growth inhibition. The sequence-speci®c eect of RIa antisense was supported by our results showing: (1) the selective downregulation of RIa mRNA level without aecting the mRNAs of other subunit of PKA, RIIa or Ca, suggesting RNase-H activation as the underlying antisense mechanism of action; (2) the selective downregulation of PKA-I (the RIa-containing PKA holoenzyme) without changing the level of PKA-II (the RIIa-containing PKA holoenzyme); and (3) inability of 4-base mismatched or random sequence control oligonucleotides to downregulate RIa or inhibit cell growth.
In addition, the RIa antisense, in a sequence-speci®c manner, brought about downregulation of EGF-R, cerbB-2 and c-erbB-3 protein levels. Importantly, like the RIa antisense-treated cells, the EGF-R antisense gene overexpressing cells also downregulated RIa/ PKA-I levels without altering PKA-II level. The RIa antisense downregulation of the EGF-R supergene family and EGF-R antisense gene downregulation of RIa/PKA-I clearly demonstrate crosstalk between the serine/threonine kinase and tyrosine kinase signaling pathways.
Several previous reports support this communication. In NRK rat ®broblasts and Nog-8 mouse mammary epithelial cells (Ciardiello et al., 1990) , TGFa and ras-induced transformation correlated with an increased expression of PKA-I along with downregulation of PKA-II. Conversely, the selective inhibition of PKA-I with a site-selective cAMP analog, 8-Cl-cAMP, resulted in downregulation of TGFa and p21 ras , upregulation of PKA-II, growth arrest and phenotypic reversion (Cho-Chung, 1990 ). More recently, an actual physical association between PKA-I and EGF-R has been shown by demonstrating the binding of RIa to the Grb2 protein (Tortora et al., 1997) .
It has been shown that PKA directly regulates the ras signaling pathway by phosphorylating raf-1 kinase (Wu et al., 1993; Cook and McCormick, 1993) and that the activated a-subunit of the heterotrimeric guanine nucleotide binding protein inhibits proliferative signals from ras through cAMP and PKA (Chen and Iyengar, 1994) . In these mechanisms of action, an increase in intracellular cAMP levels is an essential prerequisite. However, it has been shown that cellular cAMP levels do not strictly correlate with the transformation or reverse transformation processes, suggesting that cellular eectors other than endogenous cAMP levels, such as PKA, are critically involved in transformation and/or reverse transformation (ChoChung, 1990 ).
Our results show that the antisense depletion of RIa resulted in the downregulation of both basal and EGFstimulated MAP kinase activities, whereas in EGF-R antisense gene overexpressing cells, the MAP kinase activity was constitutively activated to a high level and no longer stimulated with EGF. Because both the RIa antisense and EGF-R antisense gene overexpression led to cell growth inhibition, we speculate the following mechanism of action. In RIa antisense-treated cells, the EGF pathway was downregulated but was not totally blocked and, therefore, the EGF stimulation of MAP kinase was still functional even though the activity was low. The reduced MAP kinase activity may not be due to the PKA-phosphorylation of raf-1 kinase. The PKA activity ratio, the ratio of activity in the absence of added cAMP to that in the presence of cAMP, which measures the degree of the free C subunit release, was the same during the course of the antisense treatment for 5 days (Alper and Cho-Chung, unpublished) . Thus, the RIa antisense inhibition of OVCAR-8 cell growth might involve blocking of PKA-I function in cell cycle progression as was previously shown in other cancer cells treated with RIa antisense. In HL-60 cells, RIa antisense treatment induced dierentiation and resulted in an increase in the population of cells in S phase of the cell cycle, indicating inappropriate entry of cells into S phase (Cho-Chung et al., 1997) . Assay of cyclin E demonstrated the depletion of RIa by the antisense caused deregulation of the cell cycle at two critical points, one at the entry into S phase and the other at G 2 M phase, resulting in accumulation of cells in S phase (Cho-Chung et al., 1997) , suggesting the critical role of PKA-I/RIa in the cell cycle regulation. In contrast, in EGF-R antisense gene overexpressing cells, the EGF-R pathway may be largely inhibited, if not totally blocked, and consequently cells ®nd an alternative survival pathway resulting in constitutive activation of MAP kinase. The constitutive activation of MAP kinase has been implicated as a cellular survival factor during tumor promotion (Guyton et al., 1996) .
Our results show that both cAMP and EGF signaling pathways are involved in OVCAR-8 cancer cell growth. Although these two signaling pathways crosstalk probably through PKA-I, blocking only one of these two pathways may result in activation of an alternative pathway giving rise to some advantage to cell growth. Therefore, blocking both serine/threonine kinase and tyrosine kinase pathways would be a more eective therapeutic approach to the treatment of ovarian cancer.
